Physician profile
Robert Eugene Aquino
NPI 1780671461
$4,146.56
in general payments reported to CMS, 2019-2025
29 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $545 · 2021: $1,108 · 2022: $759 · 2023: $67.32 · 2024: $515 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $936.05 | 2019-2024 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $836.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $601.81 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $230.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $159.91 | 2022-2024 | |
| Axsome Therapeutics, INC. | $149.12 | 2025 | Auvelity |
| Pfizer INC. | $143.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $119.36 | 2019-2022 | |
| Exact Sciences Corporation | $89.48 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $86.43 | 2021-2023 | |
| Dexcom, INC. | $78.63 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $63.75 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $58.42 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $43.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.08 | 2021-2022 | |
| Bausch Health US, LLC | $39.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.51 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $33.67 | 2021 | |
| Abbott Laboratories | $31.47 | 2021-2022 | |
| Organon LLC | $31.41 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.26 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $28.46 | 2025 | Pyrukynd |
| Abiomed | $19.73 | 2024 | Impella |
| Boston Scientific Corporation | $18.76 | 2024 | Varithena Administration Pack |
| Sanofi Pasteur INC. | $16.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.57 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aquino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.